Table 1.
Included MSC studies—includes all Group 1 and Group 2 studies, broken down by MSC type.
| WOMAC Scores | VAS Scores | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author/Year/ Cohort | Cell Type | Dosage | Study FU Length (Mo) | # of Joints | Pre-treatment | 6 mo | Δ 6 mo | Final FU | Δ Final FU | Pre- treatment |
6 mo | Δ 6 mo | Final FU | Δ Final FU |
| Anz 2020 [13] | BMAC | 7 mL BMAC | 12 | 45 | 35.3 | 19.4 | 15.9 | 19.4 | 15.9 | NA | NA | NA | NA | NA |
| Centeno 2014 BMAC [14] | BMAC | 90 mL BMAC | 10 | 220 | NA | NA | NA | NA | NA | 40.0 | NA | NA | 26.0 | 14.0 |
| Centeno 2015 low dose [15] | BMAC | <4E8 TNC | 11 | 67 | NA | NA | NA | NA | NA | 40.0 | NA | NA | 31.0 | 9.0 |
| Centeno 2015 high dose [15] | BMAC | >4E8 TNC | 11 | 49 | NA | NA | NA | NA | NA | 31.0 | NA | NA | 17.0 | 14.0 |
| Garay-Mendoa 2018 [16] | BMAC | 670E6 BM mononuclear cells | 6 | 26 | 35.9 | 7.9 | 28.0 | 7.9 | 28.0 | 52.7 | 9.2 | 42.8 | 9.2 | 42.8 |
| Mautner 2018 BMAC [17] | BMAC | 8ml BMAC | 6 | 58 | NA | NA | NA | NA | NA | 39 | 25 | 14 | 25 | 14 |
| Shapiro 2016 [18] | BMAC | 34E3 MSCs | 6 | 25 | NA | NA | NA | NA | NA | 31.0 | 15.0 | 11.0 | 15.0 | 11.0 |
| BMAC Means | 8.3 | 35.6 | 13.7 | 22.0 | 13.7 | 22.0 | 39.0 | 16.4 | 22.6 | 20.5 | 17.5 | |||
| Total # of Studies 6/Subgroups 7 | Total # of Joints | 490 | ||||||||||||
| Centeno 2014 BMAC/Fat [14] | BMAC & MM Fat | 90 mL BMAC, 10 mL MM fat | 11 | 103 | NA | NA | NA | NA | NA | 43.0 | NA | NA | 30.0 | 13.0 |
| Kim 2014 [19] | BMAC & MM Fat | 7 mL BMAC, 10 mL MM fat | 12 | 75 | NA | NA | NA | NA | NA | 70.0 | 35.0 | 35.0 | 33.0 | 37.0 |
| BMAC & MM Fat Means | 9.0 | NA | NA | NA | NA | NA | 56.5 | 35.0 | 35.0 | 31.5 | 25.0 | |||
| Total # of Studies 2/Subgroups 2 | Total # of Joints | 178 | ||||||||||||
| Dall’Oca 2019 [20] | MM Fat | 5–10 mL microfragmented fat | 6 | 6 | 36.3 | 19.8 | 16.5 | 19.8 | 16.5 | 46.0 | 15.0 | 31.0 | 15.0 | 31.0 |
| Hudetz 2017 [21,22] | MM Fat | 4–15 mL MM fat | 24 | 17 | NA | NA | NA | NA | NA | 39.4 | 11.7 | 27.7 | 5.5 | 33.9 |
| Mautner 2018 MM Fat [17] | MM Fat | 9 mL MM Fat | 6 | 48 | NA | NA | NA | NA | NA | 43.0 | 28.0 | 15.0 | 28.0 | 15.0 |
| Pintat 2017 [23] | MM Fat | 12 mL lipoaspirate | 12 | 18 | 34.3 | 15.7 | 18.6 | 14.1 | 20.2 | NA | NA | NA | NA | NA |
| Roato 2018 [24] | MM Fat | 35 mL MM fat | 18 | 20 | 45.9 | 15.8 | 30.1 | 13.0 | 32.9 | 70.5 | 30.1 | 40.4 | 33.4 | 37.1 |
| MM fat Means | 13.2 | 38.81 | 17.1 | 21.7 | 15.6 | 23.2 | 49.7 | 21.2 | 28.5 | 20.5 | 29.3 | |||
| Total # of Studies 5/Subgroups 5 | Total # of Joints | 109 | ||||||||||||
| Freitag 2019 1 inj [25] | ASCs | 100E6 MSC × 1inj | 12 | 9 | 38.8 | 16.3 | 22.5 | 15.4 | 23.4 | 67.0 | 29.0 | 38.0 | 26.0 | 41.0 |
| Freitag 2019 2 inj [25] | ASCs | 100E6 MSC × 2 inj | 12 | 10 | 43.8 | 26.7 | 17.1 | 12.2 | 31.6 | 65.0 | 43.0 | 22.0 | 23.0 | 42.0 |
| Jo 2017 low dose [26] | ASCs | 10E6 MSCs | 24 | 3 | 43.3 | 25.3 | 18.0 | 17.0 | 26.3 | 70.0 | 48.3 | 21.7 | 40.0 | 30.0 |
| Jo 2017 medium dose [26] | ASCs | 50E6 MSCs | 24 | 3 | 69.0 | 48.5 | 20.5 | 25.1 | 43.9 | 78.3 | 67.0 | 11.3 | 66.0 | 12.3 |
| Jo 2017 high dose [26] | ASCs | 100E6 MSCs | 24 | 12 | 54.2 | 32.8 | 21.4 | 19.0 | 35.2 | 79.6 | 44.2 | 35.4 | 45.8 | 33.8 |
| Lee 2019 [27] | ASCs | 100E6 MSCs | 6 | 12 | 60.0 | 26.7 | 33.3 | 26.7 | 33.3 | 68.0 | 34.0 | 34.0 | 34.0 | 34.0 |
| Lu 2019 [28] | ASCs | 50E6 MSCs × 2inj | 12 | 46 | 30.8 | 21.7 | 9.1 | 21.4 | 9.5 | 53.9 | 29.3 | 24.6 | 28.1 | 25.8 |
| Pers 2016 low dose [29] | ASCs | 2E6 MSCs | 6 | 6 | 60.4 | 27.2 | 33.2 | 27.2 | 33.2 | 77.0 | 35.8 | 41.2 | 35.8 | 41.2 |
| Pers 2016 medium dose [29] | ASCs | 10E6 MSCs | 6 | 6 | 41.9 | 22.8 | 19.1 | 22.8 | 19.1 | 63.7 | 36.7 | 27.0 | 36.7 | 27.0 |
| Pers 2016 high dose [29] | ASCs | 50E6 MSCs | 6 | 6 | 35.8 | 14.8 | 21.0 | 14.8 | 21.0 | 43.7 | 24.0 | 19.7 | 24.0 | 19.7 |
| Song 2018 [30] | ASCs | 20E6 MSCs | 24 | 14 | 34.8 | 20.4 | 36.8 | 12.4 | 22.4 | 49.4 | 26.2 | 23.2 | 31.7 | 17.7 |
| Spasovski 2017 [31] | ASCs | 0.5–1E7 MSCs | 18 | 11 | NA | NA | NA | NA | NA | 54.5 | 9.3 | 45.2 | 9.1 | 45.4 |
| ASCs Means | 14.5 | 46.6 | 25.7 | 22.9 | 19.5 | 27.2 | 64.2 | 35.6 | 28.6 | 33.3 | 30.8 | |||
| Total # of Studies 7/Subgroups 12 | Total # of Joints | 138 | ||||||||||||
| Al-Najar 2017 [32] | BMSCs | 30.5E6 MSCs | 6 | 13 | see Table 2 | |||||||||
| Bastos 2018 MSCs [33] | BMSCs | 40E6 MSCs | 12 | 9 | see Table 2 | |||||||||
| Bastos 2018 MSCs + PRP [33] | BMSCs + PRP | 40E6 MSCs + PRP | 12 | 9 | see Table 2 | |||||||||
| Centeno 2011 [34] | BMSCs | MSCs cultured to 2-7th passage | 11.3 | 135 | see Table 2 | |||||||||
| Davatchi 2016 [35] | BMSCs | 8–9E6 MSC | 60 | 4 | NA | NA | NA | NA | NA | 86.3 | 52.5 | 33.8 | 34.0 | 52.3 |
| Emadedin 2012 [36] | BMSCs | 20–24E6 MSC | 12 | 6 | 67.1 | 41.9 | 25.1 | 43.6 | 23.5 | 57.0 | 10.0 | 47.0 | 11.6 | 45.4 |
| Emadedin 2015 [37] | BMSCs | 0.5E6 MSCs/kg bodyweight | 30 | 6 | 69.8 | 43.7 | 26.1 | 41.7 | 28.1 | NA | NA | NA | NA | NA |
| Emadedin 2018 [38] | BMSCs | 40E6 MSCs | 6 | 19 | NA | NA | 25.7 | NA | 25.7 | NA | NA | 20.8 | NA | 20.8 |
| Lamo-Espinosa 2018 low dose [39] | BMSCs | 10E6 MSC | 48 | 10 | see Table 2 | |||||||||
| Lamo-Espinosa 2018 high dose [39] | BMSCs | 100E6 MSC | 48 | 10 | see Table 2 | |||||||||
| Orozco 2013/14 [40,41] | BMSCs | 40E6 MSCs | 24 | 12 | 18.7 | NA | NA | 7.2 | 11.5 | 46.9 | 24.8 | 22.1 | 17.0 | 29.9 |
| Soler 2016 [42] | BMSCs | 40E6 MSCs | 12 | 15 | 26.5 | NA | NA | 9.0 | 17.5 | 51.3 | 21.0 | 30.3 | 19.0 | 32.3 |
| Cultured BMD- MESC Means | 23.4 | 45.5 | 42.8 | 25.6 | 25.4 | 21.3 | 60.4 | 27.1 | 30.8 | 20.4 | 36.1 | |||
| Total # of Studies 10/Subgroups 12 | Total # of Joints | 248 | ||||||||||||
| Bansal 2017 [43] | SVF | 100E6 TNC | 24 | 10 | 64.0 | 46.0 | 18.0 | 41.0 | 23.0 | NA | NA | NA | NA | NA |
| Fodor 2016 [44] | SVF | 14.1E6 TNC | 12 | 8 | 32.9 | NA | NA | 9.4 | 32.5 | 59.0 | NA | NA | 20.0 | 39.0 |
| Garza 2020 low dose [45] | SVF | 15E6 TNC | 12 | 13 | 54.0 | 22.8 | 31.2 | 20.9 | 33.1 | NA | NA | NA | NA | NA |
| Garza 2020 high dose [45] | SVF | 30E6 TNC | 12 | 13 | 45.2 | 19.2 | 26.0 | 12.7 | 32.5 | NA | NA | NA | NA | NA |
| Gibbs 2015 [46] | SVF | 11.5E6–50E6 TNC | 12 | 7 | see Table 2 | |||||||||
| Hong 2019 [47] | SVF | 7.45E6 TNC | 12 | 16 | NA | NA | NA | NA | NA | 53.8 | 16.9 | 36.9 | 21.9 | 31.9 |
| Yokota 2017 [48] | SVF | 30E6 TNC | 6 | 26 | 49.6 | 33.8 | 15.8 | 33.8 | 15.8 | 72.7 | 49.2 | 23.5 | 49.2 | 23.5 |
| SVF Means | 12.9 | 49.1 | 30.5 | 22.8 | 23.6 | 27.4 | 61.8 | 33.1 | 30.2 | 30.4 | 31.5 | |||
| Total # of Studies 6/Subgroups 7 | Total # of Joints | 93 | ||||||||||||
| Group 1 Total Means | 14.4 | 45.1 | 25.9 | 23.0 | 20.3 | 25.2 | 56.2 | 29.6 | 28.7 | 27.1 | 28.7 | |||
| Total # of Studies 34/Subgroups 45 | Total Joints Group 1 & 2 | 1256 | ||||||||||||
TNC: Total Nucleated Cells, E6= × 106, E7= × 107, E8= × 108.